Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
Revolutionary ovarian cancer rapid test available Q4 2022
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company also raised Rs 270 crore investment from Temasek in 2019
Omega plans to further strengthen its capabilities, deepen domain expertise and build new solutions
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
Subscribe To Our Newsletter & Stay Updated
